The dilemma of transvenous cardiac rhythm devices in hemodialysis patients: time to consider the epicardial approach?

Autor: Loay Salman, Gustavo G. Lopera, Arif Asif, Roger G. Carrillo
Rok vydání: 2011
Předmět:
Zdroj: Kidney International. 79(12):1267-1269
ISSN: 0085-2538
DOI: 10.1038/ki.2011.53
Popis: A great majority of cardiac rhythm devices (pacemakers, implantable cardioverter defibrillators, and cardiac resynchronization therapy) are placed percutaneously through the central veins, across the tricuspid valve, and inserted into the endocardium. Recent data have emphasized that central venous stenosis and infection associated with transvenous leads can be observed in hemodialysis patients dialyzing with an arteriovenous access or a tunneled hemodialysis catheter.1 The development of stenosis not only produces symptoms but can also have a direct impact, decreasing dialysis dose by restricting blood flow. Because the leads of a transvenous cardiac rhythm device are directly exposed to blood, they are vulnerable to contamination during episodes of bacteremia, often necessitating the removal of a life-supporting device.1 Finally, transvenous leads can injure the valve and produce severe tricuspid regurgitation.2
Databáze: OpenAIRE